1	Sarcopenia	_	_	NNP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	first	_	_	RB	_	_	_	_	_
4	described	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	1988	_	_	CD	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	age-related	_	_	JJ	_	_	_	_	_
10	decline	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	skeletal	_	_	JJ	_	_	_	_	_
13	muscle	_	_	NN	_	_	_	_	_
14	mass	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	last	_	_	JJ	_	_	_	_	_
4	decade	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	international	_	_	JJ	_	_	_	_	_
8	groups	_	_	NNS	_	_	_	_	_
9	have	_	_	VBP	_	_	_	_	_
10	developed	_	_	VBN	_	_	_	_	_
11	operational	_	_	JJ	_	_	_	_	_
12	definitions	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	sarcopenia	_	_	NN	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	incorporate	_	_	VBP	_	_	_	_	_
17	assessments	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	muscle	_	_	NN	_	_	_	_	_
20	function	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	addition	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	muscle	_	_	NN	_	_	_	_	_
25	mass	_	_	NN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	sarcopenia	_	_	NN	_	_	_	_	_
28	case-finding	_	_	NN	_	_	_	_	_
29	guidelines	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Nonetheless	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	recent	_	_	JJ	_	_	_	_	_
4	changes	_	_	NNS	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	these	_	_	DT	_	_	_	_	_
7	recommendations	_	_	NNS	_	_	_	_	_
8	demonstrate	_	_	VBP	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	there	_	_	EX	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	significant	_	_	JJ	_	_	_	_	_
13	work	_	_	NN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	be	_	_	VB	_	_	_	_	_
16	done	_	_	VBN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	order	_	_	NN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	achieve	_	_	VB	_	_	_	_	_
21	an	_	_	DT	_	_	_	_	_
22	international	_	_	JJ	_	_	_	_	_
23	consensus	_	_	NN	_	_	_	_	_
24	on	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	methods	_	_	NNS	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	diagnose	_	_	VB	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	treat	_	_	VB	_	_	_	_	_
31	sarcopenia	_	_	NN	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	clinical	_	_	JJ	_	_	_	_	_
34	settings	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	while	_	_	IN	_	_	_	_	_
4	sarcopenia	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	now	_	_	RB	_	_	_	_	_
7	recognised	_	_	VBN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	its	_	_	PRP$	_	_	_	_	_
10	own	_	_	JJ	_	_	_	_	_
11	International	_	_	NNP	_	_	_	_	_
12	Classification	_	_	NNP	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	Diseases	_	_	NNPS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	10th	_	_	JJ	_	_	_	_	_
17	Revision	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	Clinical	_	_	NNP	_	_	_	_	_
20	Modification	_	_	NN	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	ICD-10-CM	_	_	NNP	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	code	_	_	NN	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	M62.84	_	_	CD	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	few	_	_	JJ	_	_	_	_	_
30	health	_	_	NN	_	_	_	_	_
31	care	_	_	NN	_	_	_	_	_
32	professionals	_	_	NNS	_	_	_	_	_
33	know	_	_	VBP	_	_	_	_	_
34	how	_	_	WRB	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	diagnose	_	_	VB	_	_	_	_	_
37	it	_	_	PRP	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	include	_	_	VB	_	_	_	_	_
40	it	_	_	PRP	_	_	_	_	_
41	as	_	_	IN	_	_	_	_	_
42	part	_	_	NN	_	_	_	_	_
43	of	_	_	IN	_	_	_	_	_
44	their	_	_	PRP$	_	_	_	_	_
45	clinical	_	_	JJ	_	_	_	_	_
46	practice	_	_	NN	_	_	_	_	_
47	,	_	_	,	_	_	_	_	_
48	or	_	_	CC	_	_	_	_	_
49	even	_	_	RB	_	_	_	_	_
50	recognise	_	_	VB	_	_	_	_	_
51	it	_	_	PRP	_	_	_	_	_
52	as	_	_	IN	_	_	_	_	_
53	a	_	_	DT	_	_	_	_	_
54	disease	_	_	NN	_	_	_	_	_
55	,	_	_	,	_	_	_	_	_
56	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	Special	_	_	NNP	_	_	_	_	_
3	Issue	_	_	NNP	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	Journal	_	_	NNP	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	Clinical	_	_	NNP	_	_	_	_	_
9	Medicine	_	_	NNP	_	_	_	_	_
10	was	_	_	VBD	_	_	_	_	_
11	established	_	_	VBN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	view	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	increase	_	_	VB	_	_	_	_	_
17	clinician	_	_	JJ	_	_	_	_	_
18	awareness	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	important	_	_	JJ	_	_	_	_	_
22	clinical	_	_	JJ	_	_	_	_	_
23	consequences	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	sarcopenia	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	improve	_	_	VB	_	_	_	_	_
28	understanding	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	diagnosis	_	_	NN	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	treatment	_	_	NN	_	_	_	_	_
33	strategies	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Computed	_	_	JJ	_	_	_	_	_
2	tomography	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	CT	_	_	NNP	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	provides	_	_	VBZ	_	_	_	_	_
7	precise	_	_	JJ	_	_	_	_	_
8	estimates	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	muscle	_	_	NN	_	_	_	_	_
11	quality	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	so	_	_	RB	_	_	_	_	_
14	may	_	_	MD	_	_	_	_	_
15	be	_	_	VB	_	_	_	_	_
16	useful	_	_	JJ	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	case-finding	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	sarcopenia	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	but	_	_	CC	_	_	_	_	_
23	barriers	_	_	NNS	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	this	_	_	DT	_	_	_	_	_
26	method	_	_	NN	_	_	_	_	_
27	include	_	_	VBP	_	_	_	_	_
28	high	_	_	JJ	_	_	_	_	_
29	costs	_	_	NNS	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	lack	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	availability	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	ionising	_	_	VBG	_	_	_	_	_
36	radiation	_	_	NN	_	_	_	_	_
37	doses	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Ultrasound	_	_	NN	_	_	_	_	_
2	represents	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	potentially	_	_	RB	_	_	_	_	_
5	cost-effective	_	_	JJ	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	accessible	_	_	JJ	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	safe	_	_	JJ	_	_	_	_	_
10	method	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	measuring	_	_	VBG	_	_	_	_	_
13	muscle	_	_	NN	_	_	_	_	_
14	quality	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	Harris-Love	_	_	NNP	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	colleagues	_	_	NNS	_	_	_	_	_
19	demonstrate	_	_	VBP	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	this	_	_	DT	_	_	_	_	_
22	special	_	_	JJ	_	_	_	_	_
23	issue	_	_	NN	_	_	_	_	_
24	that	_	_	IN	_	_	_	_	_
25	rectus	_	_	NN	_	_	_	_	_
26	femoris	_	_	NN	_	_	_	_	_
27	echogenicity	_	_	NN	_	_	_	_	_
28	assessed	_	_	VBN	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	ultrasound	_	_	NN	_	_	_	_	_
31	is	_	_	VBZ	_	_	_	_	_
32	significantly	_	_	RB	_	_	_	_	_
33	correlated	_	_	VBN	_	_	_	_	_
34	with	_	_	IN	_	_	_	_	_
35	intra-	_	_	JJ	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	inter-muscular	_	_	JJ	_	_	_	_	_
38	adipose	_	_	NN	_	_	_	_	_
39	tissue	_	_	NN	_	_	_	_	_
40	estimates	_	_	NNS	_	_	_	_	_
41	from	_	_	IN	_	_	_	_	_
42	CT	_	_	NNP	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	and	_	_	CC	_	_	_	_	_
45	has	_	_	VBZ	_	_	_	_	_
46	similar	_	_	JJ	_	_	_	_	_
47	associations	_	_	NNS	_	_	_	_	_
48	with	_	_	IN	_	_	_	_	_
49	muscle	_	_	NN	_	_	_	_	_
50	function	_	_	NN	_	_	_	_	_
51	and	_	_	CC	_	_	_	_	_
52	cardiometabolic	_	_	JJ	_	_	_	_	_
53	outcomes	_	_	NNS	_	_	_	_	_
54	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	clinicians	_	_	NNS	_	_	_	_	_
3	without	_	_	IN	_	_	_	_	_
4	requisite	_	_	JJ	_	_	_	_	_
5	expertise	_	_	NN	_	_	_	_	_
6	or	_	_	CC	_	_	_	_	_
7	access	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	equipment	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	perform	_	_	VB	_	_	_	_	_
12	muscle	_	_	NN	_	_	_	_	_
13	mass	_	_	NN	_	_	_	_	_
14	assessments	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	it	_	_	PRP	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	possible	_	_	JJ	_	_	_	_	_
19	that	_	_	IN	_	_	_	_	_
20	questionnaires	_	_	NNS	_	_	_	_	_
21	can	_	_	MD	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	useful	_	_	JJ	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	identifying	_	_	VBG	_	_	_	_	_
26	patients	_	_	NNS	_	_	_	_	_
27	at	_	_	IN	_	_	_	_	_
28	risk	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	sarcopenia	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	SarQoL®	_	_	NNP	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	Sarcopenia	_	_	NNP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	Quality	_	_	NNP	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	Life	_	_	NNP	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	validated	_	_	VBN	_	_	_	_	_
14	quality	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	life	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	QoL	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	questionnaire	_	_	NN	_	_	_	_	_
21	which	_	_	WDT	_	_	_	_	_
22	can	_	_	MD	_	_	_	_	_
23	discriminate	_	_	VB	_	_	_	_	_
24	sarcopenic	_	_	JJ	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	non-sarcopenic	_	_	JJ	_	_	_	_	_
27	patients	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	has	_	_	VBZ	_	_	_	_	_
30	already	_	_	RB	_	_	_	_	_
31	been	_	_	VBN	_	_	_	_	_
32	translated	_	_	VBN	_	_	_	_	_
33	into	_	_	IN	_	_	_	_	_
34	several	_	_	JJ	_	_	_	_	_
35	languages	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	issue	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	study	_	_	NN	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	validation	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	Polish	_	_	JJ	_	_	_	_	_
13	version	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	SarQoL®	_	_	NNP	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	described	_	_	VBN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	highlighting	_	_	VBG	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	potential	_	_	JJ	_	_	_	_	_
23	utility	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	this	_	_	DT	_	_	_	_	_
26	instrument	_	_	NN	_	_	_	_	_
27	for	_	_	IN	_	_	_	_	_
28	identifying	_	_	VBG	_	_	_	_	_
29	individuals	_	_	NNS	_	_	_	_	_
30	at	_	_	IN	_	_	_	_	_
31	risk	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	sarcopenia	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	as	_	_	RB	_	_	_	_	_
36	well	_	_	RB	_	_	_	_	_
37	as	_	_	IN	_	_	_	_	_
38	its	_	_	PRP$	_	_	_	_	_
39	impact	_	_	NN	_	_	_	_	_
40	on	_	_	IN	_	_	_	_	_
41	QoL	_	_	NNP	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	across	_	_	IN	_	_	_	_	_
44	a	_	_	DT	_	_	_	_	_
45	number	_	_	NN	_	_	_	_	_
46	of	_	_	IN	_	_	_	_	_
47	countries	_	_	NNS	_	_	_	_	_
48	worldwide	_	_	RB	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	Physical	_	_	JJ	_	_	_	_	_
2	function	_	_	NN	_	_	_	_	_
3	assessments	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	simple	_	_	JJ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	perform	_	_	VB	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	clinical	_	_	JJ	_	_	_	_	_
11	settings	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	most	_	_	RBS	_	_	_	_	_
16	appropriate	_	_	JJ	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	identify	_	_	VB	_	_	_	_	_
19	sarcopenia	_	_	NN	_	_	_	_	_
20	cases	_	_	NNS	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	obese	_	_	JJ	_	_	_	_	_
23	older	_	_	JJR	_	_	_	_	_
24	adults	_	_	NNS	_	_	_	_	_
25	who	_	_	WP	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	owing	_	_	VBG	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	their	_	_	PRP$	_	_	_	_	_
30	larger	_	_	JJR	_	_	_	_	_
31	muscle	_	_	NN	_	_	_	_	_
32	mass	_	_	NN	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	may	_	_	MD	_	_	_	_	_
35	generally	_	_	RB	_	_	_	_	_
36	exceed	_	_	VB	_	_	_	_	_
37	cut-off	_	_	JJ	_	_	_	_	_
38	points	_	_	NNS	_	_	_	_	_
39	for	_	_	IN	_	_	_	_	_
40	low	_	_	JJ	_	_	_	_	_
41	muscle	_	_	NN	_	_	_	_	_
42	mass	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Mesinovic	_	_	NNP	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	colleagues	_	_	NNS	_	_	_	_	_
4	demonstrate	_	_	VBP	_	_	_	_	_
5	associations	_	_	NNS	_	_	_	_	_
6	between	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	metabolic	_	_	JJ	_	_	_	_	_
9	syndrome	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	poorer	_	_	JJR	_	_	_	_	_
12	muscle	_	_	NN	_	_	_	_	_
13	function	_	_	NN	_	_	_	_	_
14	despite	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	generally	_	_	RB	_	_	_	_	_
17	larger	_	_	JJR	_	_	_	_	_
18	muscle	_	_	NN	_	_	_	_	_
19	size	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	overweight	_	_	JJ	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	obese	_	_	JJ	_	_	_	_	_
24	older	_	_	JJR	_	_	_	_	_
25	individuals	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	indicating	_	_	VBG	_	_	_	_	_
28	accelerated	_	_	VBN	_	_	_	_	_
29	loss	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	muscle	_	_	NN	_	_	_	_	_
32	quality	_	_	NN	_	_	_	_	_
33	is	_	_	VBZ	_	_	_	_	_
34	common	_	_	JJ	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	this	_	_	DT	_	_	_	_	_
37	population	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Sarcopenia	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	generally	_	_	RB	_	_	_	_	_
4	considered	_	_	VBN	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	disease	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	ageing	_	_	NN	_	_	_	_	_
9	but	_	_	CC	_	_	_	_	_
10	there	_	_	EX	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	no	_	_	DT	_	_	_	_	_
13	doubt	_	_	NN	_	_	_	_	_
14	that	_	_	IN	_	_	_	_	_
15	risk	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	developing	_	_	VBG	_	_	_	_	_
18	sarcopenia	_	_	NN	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	increased	_	_	VBN	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	numerous	_	_	JJ	_	_	_	_	_
23	medical	_	_	JJ	_	_	_	_	_
24	conditions	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	presence	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	sarcopenia	_	_	NN	_	_	_	_	_
7	appears	_	_	VBZ	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	consistently	_	_	RB	_	_	_	_	_
10	impact	_	_	VB	_	_	_	_	_
11	on	_	_	IN	_	_	_	_	_
12	prognosis	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	those	_	_	DT	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	existing	_	_	VBG	_	_	_	_	_
17	comorbidities	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	review	_	_	NN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	Han	_	_	NNP	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	colleagues	_	_	NNS	_	_	_	_	_
9	demonstrates	_	_	VBZ	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	sarcopenia	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	associated	_	_	VBN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	increased	_	_	VBN	_	_	_	_	_
16	progression	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	chronic	_	_	JJ	_	_	_	_	_
19	disease	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	postoperative	_	_	JJ	_	_	_	_	_
22	complications	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	length	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	hospital	_	_	NN	_	_	_	_	_
27	stay	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	all-cause	_	_	JJ	_	_	_	_	_
30	mortality	_	_	NN	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	cognitive	_	_	JJ	_	_	_	_	_
33	impairment	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	effects	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	sarcopenia	_	_	NN	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	cognitive	_	_	JJ	_	_	_	_	_
7	impairment	_	_	NN	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	supported	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	an	_	_	DT	_	_	_	_	_
12	original	_	_	JJ	_	_	_	_	_
13	study	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	community-dwelling	_	_	JJ	_	_	_	_	_
16	older	_	_	JJR	_	_	_	_	_
17	adults	_	_	NNS	_	_	_	_	_
18	residing	_	_	VBG	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	rural	_	_	JJ	_	_	_	_	_
21	areas	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	Korea	_	_	NNP	_	_	_	_	_
24	which	_	_	WDT	_	_	_	_	_
25	reported	_	_	VBD	_	_	_	_	_
26	that	_	_	IN	_	_	_	_	_
27	physical	_	_	JJ	_	_	_	_	_
28	frailty	_	_	NN	_	_	_	_	_
29	was	_	_	VBD	_	_	_	_	_
30	significantly	_	_	RB	_	_	_	_	_
31	associated	_	_	VBN	_	_	_	_	_
32	with	_	_	IN	_	_	_	_	_
33	poor	_	_	JJ	_	_	_	_	_
34	cognitive	_	_	JJ	_	_	_	_	_
35	function	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Liver	_	_	NN	_	_	_	_	_
2	disease	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	associated	_	_	VBN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	weight	_	_	NN	_	_	_	_	_
8	loss	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	physical	_	_	JJ	_	_	_	_	_
11	frailty	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	population-based	_	_	JJ	_	_	_	_	_
16	study	_	_	NN	_	_	_	_	_
17	reported	_	_	VBD	_	_	_	_	_
18	that	_	_	IN	_	_	_	_	_
19	non-alcoholic	_	_	JJ	_	_	_	_	_
20	fatty	_	_	NN	_	_	_	_	_
21	liver	_	_	NN	_	_	_	_	_
22	disease	_	_	NN	_	_	_	_	_
23	was	_	_	VBD	_	_	_	_	_
24	more	_	_	RBR	_	_	_	_	_
25	common	_	_	JJ	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	Korean	_	_	JJ	_	_	_	_	_
28	adults	_	_	NNS	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	low	_	_	JJ	_	_	_	_	_
31	muscle	_	_	NN	_	_	_	_	_
32	mass	_	_	NN	_	_	_	_	_
33	determined	_	_	VBN	_	_	_	_	_
34	by	_	_	IN	_	_	_	_	_
35	CT	_	_	NNP	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	regardless	_	_	RB	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	their	_	_	PRP$	_	_	_	_	_
40	obesity	_	_	NN	_	_	_	_	_
41	status	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	Similarly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	Japanese	_	_	JJ	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	chronic	_	_	JJ	_	_	_	_	_
10	liver	_	_	NN	_	_	_	_	_
11	disease	_	_	NN	_	_	_	_	_
12	reported	_	_	VBD	_	_	_	_	_
13	that	_	_	IN	_	_	_	_	_
14	50	_	_	CD	_	_	_	_	_
15	%	_	_	NN	_	_	_	_	_
16	had	_	_	VBD	_	_	_	_	_
17	low	_	_	JJ	_	_	_	_	_
18	muscle	_	_	NN	_	_	_	_	_
19	mass	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	either	_	_	CC	_	_	_	_	_
22	alone	_	_	RB	_	_	_	_	_
23	or	_	_	CC	_	_	_	_	_
24	combined	_	_	VBN	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	low	_	_	JJ	_	_	_	_	_
27	muscle	_	_	NN	_	_	_	_	_
28	strength	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	low	_	_	JJ	_	_	_	_	_
4	serum	_	_	NN	_	_	_	_	_
5	zinc	_	_	NN	_	_	_	_	_
6	concentration	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	independent	_	_	JJ	_	_	_	_	_
10	predictor	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	sarcopenia	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	these	_	_	DT	_	_	_	_	_
15	patients	_	_	NNS	_	_	_	_	_
16	suggesting	_	_	VBG	_	_	_	_	_
17	zinc	_	_	NN	_	_	_	_	_
18	supplementation	_	_	NN	_	_	_	_	_
19	warrants	_	_	VBZ	_	_	_	_	_
20	further	_	_	JJR	_	_	_	_	_
21	investigation	_	_	NN	_	_	_	_	_
22	as	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	strategy	_	_	NN	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	prevent	_	_	VB	_	_	_	_	_
27	muscle	_	_	NN	_	_	_	_	_
28	declines	_	_	NNS	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	chronic	_	_	JJ	_	_	_	_	_
31	liver	_	_	NN	_	_	_	_	_
32	disease	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_

